GLP-1 and Appetite: How Weight-Loss Drugs Rewire the Brain

What we’re looking at

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—have transformed the landscape of obesity and type 2 diabetes treatment. Originally developed to control blood sugar, these drugs produced an unexpected side effect in clinical trials: dramatic weight loss. Many patients reported simply feeling less hungry, losing interest in food between meals, and experiencing early satiety when eating [PMID 33977495]. Some even described reduced cravings for alcohol and other substances.

This review examines the mechanisms through which GLP-1-based therapies suppress appetite and influence reward pathways in the brain. Drawing on ten recent reviews and clinical analyses, we’ll explore how these medications act both centrally (in the brain) and peripherally (in the gut and other tissues) to produce their effects, what the evidence tells us about their efficacy and safety in real-world use, and what remains unknown about their long-term impact on eating behavior and metabolism.

The evidence — what studies actually found

Clinical efficacy: Weight loss beyond diabetes control

The SURPASS clinical trial program for tirzepatide—a dual GIP/GLP-1 receptor agonist—demonstrated unprecedented weight loss for a pharmaceutical intervention. Across five trials in patients with type 2 diabetes, tirzepatide at doses of 5-15 mg weekly reduced body weight by 5.4 to 11.7 kg, with 20.7% to 68.4% of participants losing more than 10% of their baseline weight [PMID 36050763]. These results exceeded those seen with semaglutide 1.0 mg weekly, the previous gold standard GLP-1 RA.

For liraglutide 3.0 mg (approved specifically for obesity management), clinical trials showed meaningful weight reduction, though generally less than the newer agents [PMID 33977495]. Semaglutide 2.4 mg weekly, investigated in phase III trials for obesity, has shown even greater efficacy. Importantly, both drugs caused “similar reductions in appetite” despite tirzepatide producing greater overall weight loss, suggesting mechanisms beyond simple appetite suppression contribute to the metabolic effects [PMID 36050763].

Real-world outcomes: The gap between trials and practice

Real-world evidence paints a more nuanced picture. Observational studies show that weight reduction in clinical practice tends to be lower than in randomized controlled trials, though outcomes approach trial results when focusing on highly adherent patients [PMID 40196933]. Discontinuation rates are sobering: 20-50% of patients stop GLP-1 RAs within the first year, often due to gastrointestinal side effects, cost barriers, or inadequate insurance coverage. Many patients also use doses substantially lower than those evaluated in clinical trials [PMID 40196933].

Despite these challenges, the medications demonstrate consistent safety profiles in real-world populations. Frequent gastrointestinal disturbances mirror trial findings, but observational studies show no clear increase in risks of severe events like pancreatitis, pancreatic cancer, or thyroid disorders [PMID 40196933]. Notably, there’s no increased risk of depression and self-harm—a concern given the medications’ effects on brain reward systems—though further evidence is needed for rare outcomes.

How it might work — biological mechanisms

The GLP-1 system: From gut to brain

GLP-1 is a 30-amino acid peptide hormone produced primarily in intestinal L-cells, released in response to meal intake [PMID 17928588]. Its physiological role extends far beyond its original identification as an “incretin hormone” (one that stimulates insulin secretion). GLP-1 functions as part of the “ileal brake”—a feedback mechanism that inhibits upper gastrointestinal motility and secretion when nutrients reach the lower small intestine, thereby optimizing nutrient absorption [PMID 12675249].

The hormone has an exceptionally short half-life, degraded within minutes by the enzyme dipeptidyl peptidase-IV (DPP-IV) [PMID 12675249]. This rapid metabolism raised an important mechanistic question: if endogenous GLP-1 never reaches high systemic concentrations, how does it exert its effects? Evidence suggests that natural GLP-1 may act primarily through sensory neurons in the intestine and liver that express GLP-1 receptors, transmitting signals to the brain via neural rather than hormonal pathways [PMID 17928588].

Pharmaceutical GLP-1 RAs circumvent this degradation through biochemical modifications that extend their duration of action, allowing them to reach GLP-1 receptors throughout the body at therapeutic concentrations [PMID 31767182].

Central pathways: Rewiring appetite and reward

GLP-1 receptors are widely distributed in brain regions controlling appetite, energy expenditure, and reward processing [PMID 39892489]. Centrally acting GLP-1 RAs modulate the release of neurotransmitters and neuropeptides that regulate hunger and satiety. The medications don’t simply create nausea that discourages eating; they appear to fundamentally alter appetite signaling.

The effects include:

• Appetite suppression: GLP-1 acts as “a physiological regulator of appetite and food intake,” not merely a pharmacological override [PMID 17928588]
• Reward modulation: GLP-1 has “implications for learning and memory, reward behavior, and palatability” [PMID 31767182], potentially explaining why some patients report reduced cravings not only for food but also for alcohol and other rewarding substances
• Satiety enhancement: Patients experience earlier feelings of fullness during meals, reducing portion sizes naturally [PMID 33977495]

These central effects are distinct from the medication’s actions on blood sugar control, explaining why GLP-1 RAs produce weight loss even in people without diabetes.

Peripheral mechanisms: Beyond the brain

Outside the central nervous system, GLP-1 RAs engage multiple pathways that contribute to weight loss and metabolic improvement:

Gastric effects: The medications delay gastric emptying—the rate at which food leaves the stomach—prolonging the feeling of fullness after eating and reducing post-meal glucose spikes [PMID 39892489]. This “enterogastrone” action is part of the ileal brake mechanism [PMID 17928588].

Metabolic regulation: Peripherally, GLP-1 RAs improve insulin secretion in a glucose-dependent manner (reducing hypoglycemia risk), suppress glucagon release, and improve overall glycemic control [PMID 39892489]. They also reduce triglycerides and LDL cholesterol, mitigate inflammation in adipose tissue, and minimize ectopic fat deposition in organs like the liver [PMID 39892489].

Pancreatic effects: Beyond acute insulin secretion, GLP-1 promotes insulin biosynthesis, insulin gene expression, and exerts trophic effects on pancreatic beta cells, including proliferation, maturation of progenitor cells, and inhibition of apoptosis [PMID 12675249].

The GIP puzzle: Dual agonism and synergistic effects

Tirzepatide’s superior efficacy compared to selective GLP-1 RAs has reignited interest in glucose-dependent insulinotropic polypeptide (GIP), the second incretin hormone [PMID 36050763]. While GIP reduces food intake and body weight in rodents, “these effects have not been demonstrated in humans,” creating a mechanistic puzzle [PMID 36050763]. Type 2 diabetic patients have been noted to be unresponsive to GIP in previous studies, yet tirzepatide’s dual agonism appears highly effective.

One hypothesis is that GIP and GLP-1 receptor activation work synergistically. Tirzepatide improved insulin sensitivity and insulin secretion more than semaglutide alone, associated with lower post-meal insulin and glucagon concentrations, despite causing “similar reductions in appetite” [PMID 36050763]. This suggests the two pathways may complement each other through mechanisms not yet fully understood.

Where the evidence is strong (and weak)

Strong evidence

The evidence base firmly establishes several key points:

1. Glucose-dependent insulin secretion: GLP-1’s incretin effect is well-characterized and consistently demonstrated across studies [PMID 29617641]
2. Appetite suppression: Multiple clinical trials confirm that GLP-1 RAs reduce hunger and food intake through both central and peripheral mechanisms [PMID 17928588, PMID 33977495]
3. Cardiovascular safety: Meta-analyses show hazard ratios below 1.0 for major adverse cardiovascular events, with confidence interval upper bounds below 1.3, meeting conventional safety definitions [PMID 36050763]
4. Gastrointestinal side effects: Nausea, vomiting, diarrhea, and constipation are consistently reported, generally mild to moderate, and most common during dose escalation [PMID 38388874, PMID 40196933]

Gaps and uncertainties

Important questions remain unanswered:

Mechanism of GIP contribution: How GIP receptor agonism enhances weight loss and whether it acts independently or synergistically with GLP-1 signaling remains unclear [PMID 36050763].

Neural versus hormonal signaling: The relative contributions of direct hormonal effects versus neural transmission through GLP-1 receptor-expressing sensory neurons are incompletely understood [PMID 12675249, PMID 17928588].

Reward pathway specificity: While GLP-1 influences reward behavior broadly, the specific circuits affected and whether the medications genuinely reduce addictive behaviors or simply alter palatability remain under investigation [PMID 31767182].

Long-term brain effects: Given that GLP-1 has neuroprotective properties and influences learning and memory, the long-term cognitive and behavioral consequences of sustained GLP-1 RA therapy require further study [PMID 34497589].

Discontinuation outcomes: What happens when patients stop these medications—regarding weight regain, metabolic rebound, and potential withdrawal effects—is inadequately characterized in real-world populations [PMID 40196933].

Practical takeaways

For patients and clinicians

GLP-1 RAs represent a paradigm shift in obesity management, offering the first pharmacological approach that rivals bariatric surgery for weight reduction in some patients. Key practical considerations include:

Realistic expectations: While clinical trials show impressive results, real-world weight loss may be more modest, particularly if patients don’t tolerate full therapeutic doses or discontinue treatment early [PMID 40196933].

Adherence matters: Outcomes approach clinical trial results in highly adherent patients, underscoring the importance of managing side effects, ensuring adequate insurance coverage, and maintaining realistic timelines for weight loss [PMID 40196933].

Gastrointestinal management: Nausea and related symptoms are common but usually transient. Gradual dose escalation, taking the medication with food (for oral formulations), and eating smaller portions can minimize discomfort [PMID 33977495].

Lifelong therapy: Because weight regain typically follows discontinuation, GLP-1 RAs may need to be continued indefinitely for sustained benefit—a consideration for cost, insurance, and patient preference [PMID 33977495].

Broader implications

The success of GLP-1 RAs has validated obesity as a disease requiring medical treatment, not merely lifestyle modification [PMID 33977495]. This may help overcome historical reluctance among healthcare systems to recognize and treat obesity pharmacologically.

Emerging multi-agonists targeting GLP-1 alongside GIP and potentially glucagon pathways may offer enhanced weight loss and metabolic flexibility [PMID 39892489]. These next-generation therapies could address obesity-related complications including cardiovascular disease, fatty liver disease, and potentially neuropsychiatric conditions, cancer risk, and musculoskeletal disease [PMID 40196933].

Limitations of this review

This synthesis has several constraints:

Publication selection: We analyzed ten review articles rather than primary research studies. While reviews provide breadth, they may not capture the most recent trial data or conflicting findings from individual studies.

Mechanistic uncertainty: Many proposed mechanisms are based on preclinical (animal) research or correlative observations in humans. Causal pathways—particularly those involving brain reward systems—remain incompletely proven.

Real-world evidence quality: Observational studies, while valuable for understanding actual clinical use, cannot establish causation for rare adverse events and may be confounded by unmeasured factors like socioeconomic status, insurance coverage, and baseline health differences.

Limited long-term data: The oldest GLP-1 RAs for obesity have been available for less than a decade. We cannot definitively characterize outcomes beyond 5-10 years of continuous use, weight trajectory after discontinuation, or very rare complications.

Scope boundaries: This review focused on appetite and reward mechanisms. We did not comprehensively address cardiovascular outcomes, effects on specific populations (elderly, adolescents, pregnant individuals), or detailed pharmacoeconomic analyses—all relevant for clinical decision-making.

Heterogeneity: Different GLP-1 RAs have varying receptor binding profiles, pharmacokinetics, and dosing regimens. Generalizations may not apply equally to all agents in the class.

Studies referenced

• PMID 36050763 — Review of tirzepatide (dual GIP/GLP-1 agonist) showing unprecedented HbA1c reduction (1.24-2.58%) and weight loss (5.4-11.7 kg) in SURPASS trials, with discussion of mechanistic questions regarding GIP contribution.

• PMID 12675249 — Early review of GLP-1 physiology and DPP-IV inhibitor therapy, highlighting GLP-1’s role in the ileal brake, trophic effects on beta cells, and rapid degradation requiring continuous administration or enzyme inhibition.

• PMID 39892489 — Comprehensive 2025 review of GLP-1 RA mechanisms covering central appetite regulation, peripheral metabolic effects including gastric emptying and insulin secretion, and emerging multi-agonist therapies.

• PMID 29617641 — Detailed mechanistic review distinguishing endogenous versus pharmacological GLP-1 action, including discussion of GLP-1R-positive cell types, inflammation, cardiovascular effects, and emerging therapeutic approaches.

• PMID 31767182 — Overview of GLP-1’s multifaceted nature including effects on insulin secretion, gastric emptying, food intake, natriuresis, and implications for reward behavior, learning, memory, and palatability.

• PMID 40196933 — Real-world evidence review showing 20-50% discontinuation rates within first year, lower weight loss than trials (except in adherent patients), frequent GI disturbances but no clear increase in severe adverse events.

• PMID 17928588 — Foundational physiology review covering GLP-1’s production in L-cells, regulation, rapid DPP-IV metabolism, role as incretin and enterogastrone, and function as physiological regulator of appetite and food intake.

• PMID 34497589 — Review of GLP-1 RA effects beyond pancreas, including neuroprotection, cardiovascular benefits, appetite suppression, metabolic regulation, and anti-inflammatory actions with discussion of tumor relationships.

• PMID 38388874 — Clinical review of tirzepatide showing superiority to dulaglutide, semaglutide, and insulin for glycemic control and weight loss, with generally well-tolerated safety profile dominated by mild-moderate GI events.

• PMID 33977495 — Review focused on GLP-1 RA mechanism in weight loss and maintenance, covering liraglutide 3.0 mg approval and semaglutide 2.4 mg trials, appetite reduction, gastric slowing, satiety enhancement, and need for lifelong therapy.